RYTM News and Press, Rhythm Pharmaceuticals Inc. From 02/28/23

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is -$0.78 (+8.2% Y/Y) and the consensus Revenue Estimate is $7.16M (+293.4% Y/Y). Over the last 1 year, RYTM has beate...

Major earning expected before the bell on Wednesday include: Amarin ( AMRN ) Lowe's Companies ( LOW ) NIO ( NIO ) Royal Bank of Canada ( RY ) Workhorse Group ( WKHS ) For further details see: Notable earnings before Wednesday's open

Rhythm Pharmaceuticals ( NASDAQ: RYTM ) announced Monday that its subsidiary, Rhythm Pharmaceuticals Netherlands B.V. acquired Xinvento B.V., a Dutch biotech focused on developing treatments for the rare genetic disease congenital hyperinsulinism (CHI). Per the terms, Rhythm B.V. will...

- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new development opportunity - - Expect to initiate clinical development in 2024 - BO...

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dis...

Summary Small caps outperformed the Nasdaq Composite last year as stocks fell due to the Federal Reserve's efforts to control inflation. Market fears are mounting that the economy may slip into a recession, but there are opportunities in small-cap stocks. The potential risk of a lon...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Rhythm Pharma ( NASDAQ: RYTM ) said on Monday that patients with a rare genetic disease called Bardet-Biedl syndrome and obesity showed clinically meaningful improvements across multiple health-related quality of life when tested with its therapy, setmelanotide, in a phase 3 tria...

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet Journal of Rare Diseases - BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rhythm Phar...

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...